A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Trial Profile

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; Varlilumab (Primary)
  • Indications Colorectal cancer; Glioblastoma; Head and neck cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results of phase I portion of this study (n=36) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 Results from the phase I portion of this trial (n = 36) published in a Celldex Therapeutics media release.
    • 17 May 2017 According to a Celldex Therapeutics media release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top